Medical Condition

nsclc

Total Trials

19

Recruiting Now

19

Trial Phases

Phase 3, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for nsclc sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
Phase 1–4 studies from early safety trials to post-marketing surveillance
NIH, pharmaceutical sponsor, and academic medical center studies worldwide
AI-powered plain-language summary available for every trial listing

Frequently Asked Questions — nsclc Clinical Trials

How many clinical trials are currently recruiting for nsclc?

ClinicalMetric currently tracks 19 actively recruiting clinical trials for nsclc, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 19. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for nsclc?

nsclc research spans Phase 1 (9 trials), Phase 2 (10 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a nsclc clinical trial?

Eligibility criteria for nsclc trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

A2 Biotherapeutics Inc. 2 trials

Revolution Medicines, Inc. 2 trials

Shanghai Chest Hospital 1 trial

Merck Sharp & Dohme LLC 1 trial

Xuanzhu Biopharmaceutical Co., Ltd. 1 trial

nsclc

Frequently Asked Questions — nsclc Clinical Trials

Recruiting Clinical Trials

Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

A Study of XZB-0004 in Patients With Solid Tumors

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC

Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.

A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

Safety and Efficacy of NK510 to Treat NSCLC

A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC